Persistent symptoms associated with long-COVID including smell loss, brain fog, and respiratory issues, tend to resolve themselves within a year for patients who suffered mild COVID-19 infection.
A new COVID-19 vaccine developed by researchers at the CNB-CSIC appears to protect against infection of the brain and neurological symptoms associated with coronavirus.
More severe COVID-19 outcomes associated with age-related macular degeneration likely arise from a genetic predisposition in addition to higher levels of Pdgf in blood serum.
Autopsy tissue samples of 44 people who died of COVID-19 showed SAR-CoV-2, the virus responsible for coronavirus, spread throughout the body and to the brain, with traces of the virus lingering for 8 months.
Gene usage in the brains of those who suffered severe COVID-19 infections was similar to that observed in the aging brain. Researchers say COVID-19 is associated with molecular signatures of brain aging.
People with PTSD had a 9% increased risk of hospitalization and an 8% increased risk of death following contracting COVID-19 than people without the disorder. Those with psychosis had a 58% increased risk of death associated with COVID-19, and those with bipolar disorder had a 29% increased risk of dying from coronavirus.
Neuroimaging study reveals significant brain changes in areas associated with language comprehension, cognition, and circadian rhythm control six months after COVID-19 infection.
People who contracted COVID-19 are significantly more likely to develop epilepsy or experience a seizure within 6 months of infection than those who contracted influenza.
Recent stressful experiences, such as the loss of a loved one or economic insecurity are strong predictors as to whether a person hospitalized for COVID-19 will experience symptoms of long COVID a year later.
Those with pre-existing anxiety, depression, chronic stress, and distress caused by loneliness are at 50% increased risk of developing Long-COVID following coronavirus infection.